To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.
Efficacy and Safety of Medtronic 780G Automated Insulin Delivery System in Adults With Type 1 Diabetes and Gastroparesis
The goal of this clinical trial is to evaluate the efficacy and safety of Medtronic 780G automated insulin delivery system in adult persons with type 1 diabetes and gastroparesis.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sana Kalaji
- Phone Number: 317-278-6017
- Email: skalaji@iu.edu
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University Health, Univeristy hospital
-
Principal Investigator:
- Viral Shah, MD
-
Contact:
- Zunera Tariq, MD
- Phone Number: 317-278-0907
- Email: tariqz@iu.edu
-
Contact:
- Viral Shah, MD
- Phone Number: 317-278-6017
- Email: tariqz@iu.edu
-
Sub-Investigator:
- Zunera Tariq, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Age ≥18 years
- Diagnosis of T1D for at least 12 months with stable insulin regimen for at least 2 months
- HbA1c ≥8.0%
- Diagnosis of gastroparesis per National Institute of Health (NIH) definition
- Willing to use Medtronic 780G system either with Simplera CGM.
- Ability to provide informed consent before any trial-related activities
- If randomized to usual care group and on an insulin pump already, should be willing to use pump in manual mode only for the duration of the study
Exclusion criteria
- Age <18 years
- Current use of inhaled insulin (Afrezza)
- Patients with T1D using any glucose lowering medications other than insulin at the time of screening
- Pregnancy, breast feeding, or wanting to become pregnant
- Current use (≥ 2 weeks of continuous use) of any steroidal medication, or anticipated long-term steroidal treatment (>4 weeks continuously), during the study period
- History of gastric outlet obstruction or other gastrointestinal structural abnormalities
- Estimated glomerular filtration rate (eGFR) <30 or on dialysis
- History of SH in the previous 3 months
- History of two or more episodes DKA requiring hospitalization in the past 12 months
- Any medical (such as severe cardiovascular disease, malignancy, chronic liver disease) or psychosocial conditions that make a person unfit for the study at the discretion of investigators
- Use of investigational drugs within 5 half-lives prior to screening
- Current use of cannabis or history of cannabinoid hyperemesis syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Medtronic 780G group
|
Participants in Medtronic AID treatment group will use it for three months |
|
No Intervention: Usual care
Participants will continue either multiple daily injections or non-AID insulin pumps |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time in Range (70-180 mg/dL)
Time Frame: Baseline to 3 months
|
Percentage of time that sensor glucose values are within the target range of 70-180 mg/dL, as measured by continuous glucose monitoring (CGM). |
Baseline to 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c
Time Frame: Baseline to 3 months
|
Change in glycated hemoglobin (HbA1c) measured using standard laboratory methods. |
Baseline to 3 months
|
|
Mean Sensor Glucose
Time Frame: Baseline to 3 months
|
Mean sensor glucose value derived from CGM data. |
Baseline to 3 months
|
|
Time in Tight Target Range (70-140 mg/dL)
Time Frame: Baseline to 3 months
|
Percentage of time that sensor glucose values are between 70 and 140 mg/dL (TTIR), measured by CGM. |
Baseline to 3 months
|
|
Time Above Range
Time Frame: Baseline to 3 months
|
Percentage of time that sensor glucose values are >180 mg/dL and >250 mg/dL, measured by CGM. |
Baseline to 3 months
|
|
Time Below Range
Time Frame: Baseline to 3 months
|
Percentage of time that sensor glucose values are <70 mg/dL and <54 mg/dL, measured by CGM. |
Baseline to 3 months
|
|
Glucose Variability
Time Frame: Baseline to 3 months
|
Glucose variability assessed by the standard deviation (SD) of sensor glucose values from CGM data. |
Baseline to 3 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Severe Hypoglycemia
Time Frame: 3 months
|
Number of severe hypoglycemic events requiring assistance from another person. |
3 months
|
|
Diabetic Ketoacidosis
Time Frame: 3 months
|
Number of diabetic ketoacidosis events defined by standard clinical criteria. |
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Endocrine System Diseases
- Metabolic Diseases
- Autoimmune Diseases
- Immune System Diseases
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Glucose Metabolism Disorders
- Diabetes Mellitus
- Paralysis
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Diabetes Mellitus, Type 1
- Gastroparesis
- Investigative Techniques
- Therapeutics
- Reproductive Techniques, Assisted
- Reproductive Techniques
- Reproduction
- Reproductive Physiological Phenomena
- Reproductive and Urinary Physiological Phenomena
- Insemination, Artificial
- Insemination
- Insemination, Artificial, Heterologous
Other Study ID Numbers
Other Study ID Numbers
- 28244
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Will be shared in future
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.